Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment.

Chahal, Harinder Singh; Capella, Peter; Presto, Ryan; Murray, Jeffrey S; Shimer, Martin; Valdez, Mary Lou; Lurie, Peter G

Chahal, Harinder Singh; Capella, Peter; Presto, Ryan; Murray, Jeffrey S; Shimer, Martin; Valdez, Mary Lou; Lurie, Peter G.

Afiliação

Chahal HS; Office of Public Health Strategy and Analysis, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA.
Capella P; Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Presto R; Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Murray JS; Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Shimer M; Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
Valdez ML; Office of International Programs, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA.
Lurie PG; Office of Public Health Strategy and Analysis, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA.

BMJ Glob Health ; 3(3): e000651, 2018.

Article em En | MEDLINE | ID: mdl-29862054

Palavras-chave

AIDS; ARV; FDA; HIV; PEPFAR; PQP; TA; USFDA; WHO; prequalification; tFDA; tentative approval

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Observational_studies Idioma: En Revista: BMJ Glob Health Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google